WASHINGTON, April 27 (Reuters) - U.S. health regulators on Friday approved Vivus Inc.'s avanafil treatment for erectile dysfunction, giving the small company, which has struggled to bring a weight loss drug to market, a potentially lucrative commercial product.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.